Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients

Table 1 Patients’ characteristics

Patient no.	Dose of peptides (mg)	HLA	Age (Y)	Gender	Stage*	PS**	Target organ
1	0.5	A2402	59	M	IIA	0	Primary tumor
2	0.5	A2402	58	M	IIB	0	Primary tumor
2	0.5	A2402	58	M	IIB	0	Lymph node
3	0.5	A2402	69	F	IVA	1	Primary tumor
3	0.5	A2402	69	F	IVA	1	Lymph node
4	1.0	A2402	64	M	III	2	Primary tumor
4	1.0	A2402	64	M	III	2	Lymph node
5	1.0	A2402	65	M	III	2	Primary tumor
5	1.0	A2402	65	M	III	2	Lymph node
6	1.0	A2402	61	M	III	0	Primary tumor
6	1.0	A2402	61	M	III	0	Lymph node
7	3.0	A2402	70	M	IIB	0	Primary tumor
7	3.0	A2402	70	M	IIB	0	Lymph node
8	3.0	A2402	63	M	IVA	0	Primary tumor
8	3.0	A2402	63	M	IVA	0	Lymph node
9	3.0	A2402	67	M	IVB	0	Primary tumor
							Lymph node
							Adrenal gland
10	3.0	A2402	71	M	III	0	Primary tumor
10	3.0	A2402	71	M	III	0	Lymph node
11	3.0	A2402	67	M	IVB	0	Primary tumor
							Lymph node
							Lung

ISSN: 1479-5876